Abstract
Phosphorescence O2 analyzer was used to measure calvarial bone cellular respiration (cellular mitochondrial O2 consumption) in Taylor Outbred mice in the presence and absence of zoledronic acid. This potent bisphosphonate inhibits osteoclast-mediated calcium resorption, and its effects on bone respiration have not been previously investigated. The change of O2 concentration with time was measured in closed vials containing phosphate-buffered saline (PBS), 5 mM glucose and 5–25 mg calvarial bone fragments, and it was complex for t = 0–30 h. Cyanide (specific inhibitor of cytochrome oxidase) halted O2 consumption, confirming the oxidation occurred in the respiratory chain. Initial rate of respiration was estimated from the zero-order plots d[O2]/dt for t = 0–4 h. For untreated specimens, the rate (mean ± SD) was 2.0 ± 1.2 µM O2 h−1 mg−1 (n = 6). This value was 7–10 times lower than that of other murine organs, but similar to that reported for rat and Guinea pig calvaria (averaging, 2.7 nmol O2 h−1 mg−1). The corresponding rate in the presence of 10–100 µM zoledronic acid was 2.7 ± 0.7 µM O2 h−1 mg−1 (n = 11), p = 0.216. The first-order plots ln ([O2] t ÷ [O2] t=0) versus time for t = 0–30 h were also used to compare treated and untreated specimens. The rate (h−1 mg−1 103) for specimens incubated in PBS without glucose was 1.3 ± 0.6 (n = 3, p = 0.007), in PBS + glucose it was 10.7 ± 6.9 (n = 10), in PBS + glucose + 10 µM zoledronic acid it was 12.1 ± 6.7 (n = 10, p = 0.579), in PBS + glucose + 20 µM zoledronic acid it was 12.9 ± 3.3 (n = 9, p = 0.356), and in PBS + glucose + 100 µM zoledronic acid it was 13.7 ± 7.7 (n = 9, p = 0.447). Thus, exposure to high-doses of zoledronic acid over several hours imposed a statistically insignificant increase in calvarial bone cellular respiration.
Similar content being viewed by others
Abbreviations
- Pd phosphor:
-
Pd(II) complex of meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin
- PBS:
-
Phosphate-buffered saline
- MEM:
-
Minimum essential medium alpha modification
- NaCN:
-
Sodium cyanide
- GO:
-
Glucose oxidase
References
Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714–1723
Reid DM, Devogelaer J-P, Saag K (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 273:1253–1263
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822
Balesmans W, Van Wesenbeeck L, Van Hul W (2005) A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int 77:263–274
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 Suppl:2961–2978
Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, Mönkkönen J (2006) A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147:437–445
Evans CE, Braidman IP (1994) Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 26:95–107
Gasser JS, Ingold P, Venturiere A, Shen V, Green JR (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23:544–551
Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860
Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62
Hynes J, Marroquin LD, Hynes J, Marroquin LD, Ogurtsov VI, Christiansen KN, Stevens GJ, Papkovsky DB, Will Y (2006) Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol Sci 92:186–200
Schirrmacher K, Lauterbach S, Bingmann D (1997) Oxygen consumption of calvarial bone cells in vitro. J Orthop Res 15:558–562
Alsamri MT, Al-Shamsi M, Al-Salam S, Marzouqi F, Al-Mansouri A, Al-Hammadi S, Balhaj G, Al Dawaar SK, Al-Hanjeri RS, Benedict S, Sudhadevi M, Conca W, Penefsky HS, Souid A-K (2011) Measurement of oxygen consumption by murine tissues in vitro. J Pharmacol Toxicol Methods 63:196–204
Casanova M, Herelle J, Thomas M, Softley R, Schindeler A, Little D, Schneider P, Müller R (2016) Effect of combined treatment with zoledronic acid and parathyroid hormone on mouse bone callus structure and composition. Bone 92:70–78
Author information
Authors and Affiliations
Contributions
Author contributions
The manuscript was written through contributions of all the authors. All the authors have given approval to the final version of the manuscript. The technical assistance of Mr. TP is greatly appreciated.
Corresponding author
Ethics declarations
Funding sources
This research was supported by a Grant from the United Arab Emirates University.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Alsamri, M.T., Al-Hammadi, S., Islam, B. et al. Zoledronic acid and bone cellular respiration. J Bone Miner Metab 36, 392–398 (2018). https://doi.org/10.1007/s00774-017-0850-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-017-0850-7